After PSM, similar results were observed.<h4>Conclusions</h4>There was no significant difference in OS between osimertinib and 1G/2G EGFR-TKIs as 1L treatment in patients with EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.